Printer Friendly

PRRS Vaccine Market 2018 Forecasts for China: Porcine Reproductive & Respiratory Syndrome is a Major Attraction for Animal Health Enterprises.

DALLAS, March 13, 2015 /PRNewswire/ --

LifeScienceIndustryResearch.com adds China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry, 2014-2018 market research of 50 pages, published in Sep 2014, to the Pharmaceuticals intelligence collection of its store.

According to National Compulsory Immunization Plan of Animal Epidemic Diseases in 2014 issued by Ministry of Agriculture of China, the government conducts compulsory immunizations against 4 diseases, including highly pathogenic PRRS. The government is responsible for the expenses. Currently highly pathogenic PRRS vaccines are purchased by the government through invitation for bidding in China.

The market competition is intensive in the PRRS vaccine industry in China. There are 26 manufacturers of PRRS vaccines in China, including Dahuanong, Xinjiang Tecon Animal Husbandry BioTechnology Co., Ltd., Qingdao Yebio Bioengineering Co., Ltd. and Inner Mongolia Jinyu Group Stock Company. In terms of the direct sales of high end vaccines, the PRRS vaccines of Zoetis went to the market in Guangzhou at the end of August 2013 after Boehringer. These foreign funded vaccine brands occupy the market shares using the brand advantages, which intensify the market competition.

As Chinese economy develops and the living standards increase, the demand for pork will continue to grow, which promotes the development of pig raising industry. The market size of PRRS vaccines will continue to increase in China in the next few years, which attract many animal health enterprises' attention.

Order a copy of this report ( Research Report on China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry, 2014-2018 ) at (Prices start at US $ 18 00 for a single user PDF) http://www.lifescienceindustryresearch.com/purchase?rname=22861

China is the world's largest producer and consumer of pork with the output volume of pork accounting for nearly 50% of the total. The output volume of pork was 54.93 million tons in China in 2013, up by 2.8% YOY. The livestock volume of pigs was 474.11 million, down by 0.4% YOY while the stock volume of fattened pigs was 715.57 million, up by 2.5% YOY.

The PRRS broke out in southern China and spread rapidly nationwide after summer in 2006, which lead to increases in mortality rate of piglets and pork prices and significant decrease in output volume of pork. In May 2007, the Ministry of Agriculture of China approved the production of highly pathogenic porcine reproductive and respiratory syndrome inactivated vaccine (NVDCJXA1) in six manufacturers of biological products. Porcine reproductive and respiratory syndrome (PRRS) remains one of the key compulsory immunity diseases in China.

Through this report, the readers can acquire the following information:

* Incidence Status of Porcine Reproductive and Respiratory Syndrome

* Status of China Breeding Industry

* Policy Environment and Government Procurement of PRRS Vaccines in China

* Supply and Demand Status of PRRS Vaccines in China

* Major Manufacturers of PRRS Vaccines and the Operation Status in China

* Prospect of China PRRS Vaccine Industry in China

The Following Enterprises and People Are Recommended to Purchase This Report:

* Manufacturers and Trading Enterprises of Animal Vaccines

* Breeding Enterprises

* Management Organizations of Livestock Industry

* Investors and Research Institutes Concerned about PRRS Vaccine Industry

In China, PRRS is the most serious disease that impairs the pig raising & breeding industry. It inflicted heavy losses on China pig raising & breeding industry for many times.

In April 2007, Ministry of Agriculture of China issued Technical Standards of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Prevention and Treatment, and classified HP-PRRS into serious animal epidemic diseases which are covered by the national compulsory immunization program. Based on National Compulsory Immunization Plan of Animal Epidemic Diseases 2013, China government conducts compulsory vaccinations for all pigs against HP-PRRS. In order to identify various strains, local governments must take effective measures and ensure every county only use one kind of live HP-PRRS vaccines to immunize pigs.

With the increasing living standards of Chinese people, the demand for pork keeps growing accordingly. In 2012, the output volume of pork in China was 53.35 million tons, increasing by 5.6%. In 2012, China also imported 522,000 tons of pork, increasing by 11.7% YOY. At the end of 2012, the livestock volume of pigs in China was 474.92 million, increasing by 1.6% YOY; the fattened volume was 696.28 million in 2012, increasing by 5.2%. The scale expansion of the pig raising & breeding industry causes increasing demand for PRRS vaccines in China.

At present, more than 20 enterprises are qualified to produce PRRS vaccines in China (about 40 factories). For a long time, only one foreign enterprise Boehringer was approved to enter Chinese market with its PRRS vaccines. In August 2013, live attenuated HP-PRRS vaccines (Ruilan'an) produced in China by Zoetis of Pfizer was officially approved to be launched into Chinese market.

In China, the government provides HP-PRRS vaccines to all pig raising & breeding enterprises and households for free, but there are various problems during vaccine production, transportation, etc. Therefore, many enterprises and households prefer to purchase vaccines, to avoid the occurrence of PRRS. In the next few years, it is predicted that the scale of China pig raising & raising & breeding industry will keep increasing, the intensive raising & breeding mode will be improved and the demand for PRRS vaccines will keep growing. For international animal vaccine producing enterprises, they will find huge market opportunities in China.

Complete report (Research Report on China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry, 2013-2017) is available at (Prices start at US $ 1300 for a single user PDF) @ http://www.lifescienceindustryresearch.com/research-report-on-china-porcine-reproductive-and-respiratory-syndrome-prrs-vaccine-industry-2013-2017.html Or Order a copy of this report @ http://www.lifescienceindustryresearch.com/purchase?rname=7001

Browse more reports on "Pharmaceuticals" @ http://www.lifescienceindustryresearch.com/category/pharmaceuticals

About Us:

Life Science Industry Research brings to you to the latest reports in market research on Biotechnology, Diagnostics, Healthcare, Medical Devices and Pharmaceuticals segments from leading research publishers across the globe. These reports also cover data and information on sub-segments and sectors under these life sciences categories.

Connect with Us:

G+ / Google Plus: https://plus.google.com/112612135957880308475/posts

Twitter: https://twitter.com/LifeSciReports

RSS / Feeds: http://www.lifescienceindustryresearch.com/feed

Contact:

Ritesh Tiwari

TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252

Tel: +1-888-391-5441 sales@lifescienceindustryresearch.com
COPYRIGHT 2015 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Geographic Code:9CHIN
Date:Mar 13, 2015
Words:1278
Previous Article:Celebrate 'National Lost Sock Day' with a Henry J Sock Subscription.
Next Article:Samsung Bioepis Submits Marketing Authorization Application For SB2, A Remicade (Infliximab) Biosimilar Candidate, To The European Medicines Agency.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters